Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.56 |
| ▸ | ABAT | P80404 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572456 | 1.00 | HPGD (0.62) | HPGDMAPK1GPR35TP53TSHR | |
| Hydrogen Sulfide SCHEMBL28313840 | 0.98 | HPGD (0.60) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL10435240 | 0.91 | CA12 (0.57) | HPGDMAPK1GPR35TP53TSHR | |
| Nitrophenolate SCHEMBL28780638 | 0.91 | GPR35 (0.53) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL229798 | 0.83 | GPR35 (0.62) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL29751827 | 0.83 | GPR35 (0.62) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL28259735 | 0.82 | GPR35 (0.60) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL1561802 | 0.80 | TSHR (0.56) | HPGDMAPK1GPR35TSHRALDH1A1 | |
| SCHEMBL27895839 | 0.80 | CTSB (0.61) | HPGDMAPK1GPR35TP53TSHR | |
| SCHEMBL46705 | 0.79 | TTR (0.47) | HPGDMAPK1GPR35TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775165-A | Multi-phase force stimulus response luminescent material and preparation and application thereof | 中国航发商用航空发动机有限责任公司 | 2025-04-08 | — | — | CN | claimed |
| CN-114113370-B | Analysis method of aromatic halogenated disinfection byproducts in water | 东南大学 | 2024-03-26 | — | — | CN | claimed |
| CN-116514661-B | Continuous flow synthesis method of 4-bromo-2-nitrophenol | 研峰科技(北京)有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116514661-A | Continuous flow synthesis method of 4-bromo-2-nitrophenol | 研峰科技(北京)有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-111302956-B | Preparation method of 4-bromo-2-aminophenol | 国药集团化学试剂有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-114113370-A | Analysis method of aromatic halogenated disinfection byproducts in water | 东南大学 | 2022-03-01 | — | — | CN | claimed |
| CN-109096043-B | Synthesis method of 2, 5-dibromoiodobenzene | 盐城师范学院 | 2021-03-12 | — | — | CN | claimed |
| CN-111302956-A | Preparation method of 4-bromo-2-aminophenol | 国药集团化学试剂有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-110407702-A | A kind of preparation method of eltrombopag olamine key intermediate 3 '-amino -2 '-xenol -3- carboxylic acid | WUHAN INST TECHNOLOGY | 2019-11-05 | — | — | CN | claimed |
| CN-109651295-A | A kind of synthesis technology of 2- isopropoxy -4- morpholine aniline | 南京诺希生物科技有限公司 | 2019-04-19 | — | — | CN | claimed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | claimed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | claimed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | HPGD 3157/4885MAPK1 3625/4885GPR35 1441/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | HPGD 2985/4885MAPK1 3250/4885GPR35 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.